The dawning of a new era in the Pharma, Medical and Biotech (PMB) sector was catalyzed by the macro events of 2020. The rise of the pandemic at the beginning of the year catapulted forward segments in the PMB sector that were historically less prone to innovation and that arguably were previously undervalued. CDMOs are a burgeoning industry and are becoming more specialized in their focus across the board, according to Michelle Tong, partner in the Private Equity group and Private Investment Funds practice at Goodwin. Read the Mergermarket article here.
In The Press January 29, 2021